BOLT
Bolt BiotherapeuticsNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$9.47M
P/E Ratio
—
EPS
$-17.85
Beta
0.86
52W High
$9.25
52W Low
$3.91
50-Day MA
$4.92
200-Day MA
$5.38
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the discovery, development and commercialization of pharmaceutical products. The company is headquartered in Redwood city, California.
Fundamentals
| Revenue (TTM) | $7.70M |
| Gross Profit (TTM) | $-20.84M |
| EBITDA | $-33.34M |
| Operating Margin | -224.20% |
| Return on Equity | -79.70% |
| Return on Assets | -27.70% |
| Revenue/Share (TTM) | $4.12 |
| Book Value | $13.80 |
| Price-to-Book | 0.32 |
| Price-to-Sales (TTM) | 1.23 |
| EV/Revenue | 0.508 |
| EV/EBITDA | 0.93 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 90.10% |
| Shares Outstanding | $1.92M |
| Float | $1.77M |
| % Insiders | 7.10% |
| % Institutions | 25.26% |
Data last updated: 4/7/2026